Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy  

作　　者：Yue Shen Jie-Qi Chen Xiang-Ping Li 

机构地区：[1]Department of Pharmacy,Xiangya Hospital,Central South University,Changsha,Hunan 410008,China [2]National Clinical Research Center for Geriatric Disorders,Xiangya Hospital,Central South University,Changsha,Hunan 410008,China

出　　处：《Genes & Diseases》2025年第3期297-318,共22页基因与疾病(英文)

基　　金：supported by the Hunan Provincial Natural Science Foundation of China(No.2023JJ50013);the Department of Science and Technology of Hunan Province,China(No.2022ZK4052);the Independent Exploration and Innovation Project for Graduate Students of Central South University(No.2024ZZTS0286).

摘　　要：With the rapid advancements in second-generation gene sequencing technologies,a growing number of driver genes and associated therapeutic targets have been unveiled for lung adenocarcinoma(LUAD)and lung squamous cell carcinoma(LUSC).While they are clinically classified as non-small cell lung cancer(NSCLC),they display distinct genomic features and substantial variations in clinical efficacy,underscoring the need for particular attention.Hence,this review provides a comprehensive overview of the latest advancements in driver genes,epigenetic targets,chemotherapy,targeted therapy,and immunotherapy for LUAD and LUSC.Additionally,it delves into the distinctions in signaling pathways and pivotal facets of clinical management specific to these two categories of lung cancer.Moreover,we furnish pertinent details regarding clinical trials pertaining to driver genes and epigenetics,thus establishing a theoretical foundation for the realization of precision treatments for LUAD and LUSC.

关 键 词：Clinical efficacy Gene mutations Lung adenocarcinoma(LUAD) Lung squamous cell carcinoma(LUSC) Therapeutic targets 

分 类 号：R734.2[医药卫生—肿瘤]